TTC3-AS1: A Promising Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Target Name: TTC3-AS1

NCBI ID: G100874006

TTC3-AS1

Other Name(s): TTC3 antisense RNA 1 | TTC3 antisense RNA 1 (non-protein coding)

TTC3-AS1: A Promising Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Alzheimer's disease is a debilitating and progressive neurological disorder that affects millions of people worldwide. It is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, leading to cognitive decline and eventually, death. Currently, there is no cure for Alzheimer's disease, and the only available treatment is supportive care, which aims to alleviate symptoms and improve quality of life. Therefore, the development of new drug targets and biomarkers for the early detection and treatment of Alzheimer's disease remains a promising area of research.

TTC3-AS1: A Potential Drug Target

TTC3-AS1 is a transmembrane protein that is expressed in various tissues and organs, including brain. It is a member of the TTC3 gene family, which encodes a protein involved in the regulation of cell adhesion and signaling. The loss of TTC3-AS1 has been observed in various neurodegenerative diseases, including Alzheimer's disease.

In recent years, researchers have identified TTC3-AS1 as a potential drug target for the treatment of Alzheimer's disease. Several studies have shown that TTC3-AS1 is involved in the regulation of the expression of genes involved in neurodegeneration, including the presenilingenylated RNA (PSR) gene. PSR is a gene that encodes for a protein involved in the production of presenilingenylated RNA, which is a hallmark of neurodegenerative diseases.

In addition, TTC3-AS1 has been shown to be involved in the regulation of the neurotransmitter dopamine, which is involved in the transmission of signals in the brain. The loss of dopamine-producing neurons is a hallmark of Alzheimer's disease, and recent studies have shown that TTC3-AS1 is involved in the regulation of dopamine production and function.

Furthermore, TTC3-AS1 has been shown to be involved in the regulation of the microtubule dynamics, which is involved in the transport of neurotransmitters and other molecules in the brain. The misfolding of microtubules has been implicated in the development of neurodegenerative diseases, including Alzheimer's disease.

TTC3-AS1 as a biomarker

TTC3-AS1 has also been shown to be a potential biomarker for the early detection of Alzheimer's disease. The loss of TTC3-AS1 has been observed in the brains of individuals with Alzheimer's disease, and the levels of TTC3-AS1 have been shown to be decreased in the brains of individuals with the disease compared to age-matched controls.

In addition, the levels of TTC3-AS1 have been shown to be associated with the level of beta-amyloid plaque formation in the brains of individuals with Alzheimer's disease. Beta-amyloid is a hallmark of Alzheimer's disease, and the accumulation of beta-amyloid in the brain is thought to contribute to the development and progression of the disease.

TTC3-AS1 as a drug target

The potential drug target for TTC3-AS1 is the regulation of its expression and function. Researchers have identified several potential drug targets for TTC3-AS1, including the inhibition of the androgen receptor, the modulation of the activity of the microtubule, and the inhibition of the activity of the protein kinase CKL.

The inhibition of the androgen receptor is thought to be a potential mechanism of action for TTC3-AS1. Androgens, such as androstenedione, have been shown to play a role in the development and progression of Alzheimer's disease. The androgen receptor is involved in the regulation of androgens

Protein Name: TTC3 Antisense RNA 1

The "TTC3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets